Clinical Study
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
Table 3
Hematologic and nonhematologic toxicities during bortezomib retreatment therapy according to the NCI-CTCAE 4.0.
| Grade | Number of patients in total 30, (%) | 1 | 2 | 3 | 4 |
| Leukopenia | 5 (17) | 9 (30) | 8 (27) | 3 (10) | Neutropenia | 3 (10) | 8 (27) | 9 (30) | 5 (17) | Anemia | 8 (27) | 15 (50) | 3 (10) | 0 | Thrombocytopenia | 5 (17) | 10 (33) | 7 (23) | 6 (20) | Creatinine | 2 (7) | 3 (10) | 1 (3) | 0 | Anorexia | 8 (27) | 0 | 0 | 0 | Nausea | 6 (20) | 1 (3) | 0 | 0 | Vomiting | 1 (3) | 1 (3) | 0 | 0 | Diarrhea | 2 (7) | 3 (10) | 0 | 0 | Constipation | 5 (17) | 3 (10) | 0 | 0 | Dyspnea | 3 (10) | 1 (3) | 0 | 0 | Pneumonia | 0 | 0 | 5 (17) | 0 | Fever/bacteremia | 0 | 0 | 3 (10) | 0 | Sensory neuropathy | 10 (33) | 8 (27) | 1 (3) | 0 | Motor neuropathy | 4 (13) | 1 (3) | 1 (3) | 0 | Pain | 10 (33) | 4 (13) | 0 | 0 | Dizziness | 11 (37) | 0 | 0 | 0 | Delirium | 1 (3) | 0 | 0 | 0 | Insomnia/somnolence | 6 (20) | 0 | 0 | 0 | Asthenia | 9 (30) | 11 (37) | 1 (3) | 0 | Rash | 2 (7) | 0 | 0 | 0 |
|
|
NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.
|